Flogging (see my last post) wasn't the only way that the nineteenth-century army left permanent marks upon soldiers bodies. It is shocking to today's sensibilities, but miscreant soldiers were branded. Or, to be technical, forcibly tattooed. Men had been branded with a hot iron in the seventeenth century, as this artifact from the reign of Charles I shows.
Some shades of political opinion were revolted by the practice of branding. It implied that free men, volunteer soldiers, were akin to cattle. 6 It also echoed practices of slave ownership, where human chattels were marked with an owner's brand. Yet public opinion was not particularly exercised by the issue of branding, compared to its opposition to flogging. Of course, branding was also strongly associated with criminality. Until 1789, a convicted criminal could be branded on the thumb with 'T' for theft, 'F' for felon or 'M' for murder. 7 While the parallels between criminal and military punishment outraged public opinion in the case of flogging, branding did not arouse the same feelings. Politicians expressed surprise that branding even existed, suggesting that awareness of it was relatively low. 8 Being a shorter and necessarily quieter punishment than flogging, civilians were unlikely to hear the cries of soldiers being marked. It may be that the earlier cessation of branding in a criminal context meant that it quickly fell from public knowledge. However, flogging endured as a criminal punishment until the early 1830s, 9 which may explain greater public revulsion to it as a military punishment in the nineteenth century. Branding was finally abolished in 1879, just before flogging in 1881.
This entry was posted in Barracks, Britain, Court Martial, Flogging, History, Ireland, Military, Punishment, Slavery, Tattoo. Bookmark the permalink.


Three times a month, a growing group of dedicated church members and neighboring friends meet to help bring comfort to those in need by way of prayer shawls. These shawls, lap robes, hats and pocket prayers are knitted or crocheted and given to anyone in need.
Besides exhibiting an unrivaled talent for beautiful work, the members have a passion for finding ways to bring comfort to others — whether they're suffering from illness, personal crisis or loss of a loved one. The projects have been shared with many local friends and have even found their way across the country.
If you have a knack for knitting or crocheting, enjoy fellowship, conversation and prayer, and a desire for doing good, perhaps the Prayer Shawl Ministry is for you. The group meets on the second Tuesday of the month at 6:30, the third Wednesday at 1:00, and the fourth Thursday at 6:30.


CBA offers educational and training program that cover a wide spectrum of topics and training opportunities. Some are degree oriented and involve longer committments, while others are subject specific courses or partial day training. Whether your looking for specialized, specific training to improve your knowledge and skills in one area, or if your looking to develop broad management skills that will help you progress your career long term, CBA has solutions for you.


Kraft Mac & Cheese Recall - Check Your Boxes!
If you've got boxes of Kraft Mac & Cheese in your cupboard , get them out and check them for this recall. Kraft is recalling 242,000 cases of mac & cheese that may have metal pieces in them!
The company recalled 7.25-ounce size boxes of Kraft original flavor macaroni & cheese with "best when used by" dates of Sept. 18, 2015, through Oct. 11, 2015, with "C2" directly below the date. The "C2" refers to the production line on which the affected products were made.
If you have any of the recalled boxes return them for an exchange or a refund to the stores where you bought the items. You can also call Kraft consumer relations at 800-816-9432 from 9 a.m. to 6 p.m. Eastern time.
You can read more about the recall HERE.


text:
Jules Bender (1914 – January 13, 1982) was an American collegiate and professional basketball player.  He was an All-American at Long Island University, leading the Blackbirds to a 103–6 record over his career.

Bender was a native of Brooklyn, New York, and attended Boys High School. He went on to play college basketball at Long Island University from 1934 to 1937.

College
Bender came to L.I.U. to play for future Hall of Fame coach Clair Bee.  During Bender's four-year career, the Blackbirds went a remarkable 103–6, including a perfect 24–0 in the 1935–36 season, with Bender leading the New York City metropolitan area in scoring, a feat he also accomplished the previous season. At the completion of the 1936 season, Bender was named the winner of the inaugural Haggerty Award, presented since to the top player in the New York City metropolitan area each year.

After the 1936 season, the L.I.U. Blackbirds were invited to try out for the 1936 Olympics, the first year in which basketball would be an event.  In a move that surprised many, the largely Jewish team, including Bender, boycotted the trials over the games' placement in Berlin, Germany and the anti-semitic leanings of the country's leader Adolf Hitler.

Bender was named a Consensus All-American in 1937. He was inducted into the L.I.U. Athletics Hall of Fame in 2000 (their inaugural class).

Professional
After his college career, Bender played in the American Basketball League for Kate Smith's Celtics, the Kingston Colonials, Wilkes-Barre Barons, Baltimore Clippers and the Paterson Crescents.  Following his professional career he became a high school teacher at his alma mater, Boys High School and then at John Dewey High School, both in Brooklyn. He also coached at the college level for Brooklyn College and the United States Merchant Marine Academy.

Bender died of cancer on January 13, 1982. He was buried at Mount Hebron Cemetery in Flushing, Queens.

References

External links
 Jews in Sports profile
 LIU Hall of Fame profile

1914 births
1982 deaths
All-American college men's basketball players
American men's basketball players
Baltimore Bullets (1944–1954) players
Basketball coaches from New York (state)
Basketball players from New York City
Boys High School (Brooklyn) alumni
Brooklyn Bulldogs men's basketball coaches
Deaths from cancer in Florida
High school basketball coaches in New York (state)
Jewish American sportspeople
Jewish men's basketball players
LIU Brooklyn Blackbirds men's basketball players
Merchant Marine Mariners men's basketball coaches
Paterson Crescents players
Sportspeople from Brooklyn
Forwards (basketball)
Guards (basketball)
Brooklyn College faculty
Burials at Mount Hebron Cemetery (New York City)
20th-century American Jews

redpajama_set_name: RedPajamaWikipedia


text:
Stylewatch
Stylewatch: Hole in 1995
It's rumoured that Courtney Love's band might reform – making this the perfect time to revive their influential 90s look
Lauren Cochrane
Tue 10 May 2016 09.01 EDT Last modified on Mon 2 Jul 2018 09.57 EDT
Courtney Love and friends: Hole at the height of their fame. Photograph: Kevin Cummins/Getty Images
Courtney Love has always been a woman with the appeal of Marmite. The love/hate thing dates back to the 90s – and has links to a style of dress that came to be known as "Kinderwhore". Think slip dresses, ripped tights, peroxide hair and lipstick applied with the dexterity of a six-year-old.
Love was courting controversy from the start with the thrift-store mixture of childlike shapes, cute hairgrips and the rips and tears of punk, and she was also challenging the slick glamour of 80s femininity. The look was worn by women in the grunge scene – including Kat Bjelland of Babes in Toyland, who supposedly coined the term – they were grown-ups dressed as dolls left out in the garden over night: pretty but grubby. The look went viral when it was faithfully replicated by Hole's fans, who had been watching the Miss World video on repeat. Those haters inevitably hated.
Now, more than 20 years on, and its influence on fashion is undeniable. Love is a regular on the front row of shows including Givenchy, and now-disbanded London duo Meadham Kirchhoff dedicated their spring/summer 2012 show to Love, with an army of lookalikes in slipdresses and blonde wigs. It's already had its homage this year in the shape of Saint Laurent's spring collection which, with its slipdresses and tiaras, is basically Courtney goes haute. And, with the news that Hole may be reforming, expect more to see Kinderwhore reworked for a new decade.
Of course, as this picture demonstrates, there were other members of the band, too, who were less Kinderwhore inclined. Notably Melissa Auf Der Maur, the bassist who replaced Kristen Pfaff in 1994. While Love's look is all about extreme reactions, Auf Der Maur might be a happy medium.
Pull on a skinny knit, a pendant and find yourself a matt red lipstick. Your Hole tribute will be coolly understated, and without a ripped slip dress in sight.

redpajama_set_name: RedPajamaCommonCrawl


text:
Home > Unlabelled > Perahera in Jaffna 2009
Perahera in Jaffna 2009
"The perahera was not spiritual but yet another example of religion being put to political purpose. It was drama, a play deliberately "staged" to try to humiliate Tamils; to try to persuade them to accept that they are a beaten and conquered people; powerless even to protest peacefully..."
By Charles Sarvan
Perahera in Jaffna.
(November 04, Jaffna, Sri Lanka Guardian) "The 51st Division of Sri Lanka Army (SLA) in Jaffna conducted the 'Kathina Pooja' perahera Thursday night [22nd October 2009] led by Namal Rajapakse, the son of Sri Lankan President Mahinda Rajapaksa, who had come along with 250 youths and 20 Buddhist priests from the South to participate in the perahera."
Religious processions are usually conducted in order to affirm and strengthen the faith of a people: a Christian pageant usually takes place in a Christian region; a Buddhist procession among an essentially Buddhist population, and so on. But Jaffna is overwhelmingly Hindu. Secondly, this particular perahera was organised, conducted and controlled by the army. There was nothing in it of the Buddha's teaching of love, compassion and peace. The perahera was not spiritual but yet another example of religion being put to political purpose. It was drama, a play deliberately "staged" to try to humiliate Tamils; to try to persuade them to accept that they are a beaten and conquered people; powerless even to protest peacefully. (Tamils, including those who were / are against the Tigers, will acknowledge that, during the time of the LTTE, though the Tigers had lost control of Jaffna, the Sinhalese government would not have dared display such contempt.)
One of the pictures accompanying the report of the perahera reveals Douglas Devananda sitting in the front row, participating in the attempt to heap humiliation on his people. But this kind of behaviour is not peculiar to the Tamils of Sri Lanka. Why do we have the words "boycott" and "quisling" in the English language? They have now ceased to be proper nouns and have become modifiers, but what is their origin? Didn't the Vichy government, composed of Frenchmen, cooperate with the Nazis who had conquered France? Haven't puppets elsewhere and throughout time collaborated with occupying forces? It is not a Tamil, but a human, failing, albeit in a minority.
Reaction of some Tamils
When confronted with total defeat and complete subjugation, facing (apparent) hopelessness, there is a tendency in some to turn to "self-blame", even to "self-hate." So it is that when I mentioned the perahera "dramatised" in Jaffna to a fellow Tamil, his reaction was to say that, recently, a Hindu festival was celebrated in Vavuniya by Tamils while not far away other Tamils endure the misery of concentration camps. "Given our innate Tamil nature, we Tamils have earned [deserve] what we've got."
"The Tamils of Sri Lanka are no better or worse than other human beings, and a struggle is lost only if the people, taking a negative and fatalistic attitude, give it up as hopeless. No people (Tamils of Sri Lanka included) "deserve" occupation, subjection and subordination; humiliation and exploitation."
This reaction too one has observed in other peoples, in other places, and at other times when confronted with defeat and apparent hopelessness. Instead of others blaming the victims (the "blame-the-victim" syndrome), it becomes an instance where the victims develop a sense of unworthiness; masochistically blame themselves. It is rather like an animal which, no longer able to attack the one who caused its injury; in pain and powerlessness, in frustration and despair, turns and bites its own wound.
Besides, putting the blame on the (alleged) nature of the Tamils placates our conscience; becomes an excuse, enabling us not to take an interest, show concern or be active. Such emotional and psychological responses, though perhaps understandable, must be guarded against because they are not positive and constructive; because they do not build courage, give hope, strengthen resolve. On the contrary, they breed resignation, acceptance, inaction, passivity. At root, such reactions are surrender: "It is hopeless, futile. We deserve no better." This becomes collaboration and cooperation with the aims and intentions of the oppressor.
The Tamils of Sri Lanka are no better or worse than other human beings, and a struggle is lost only if the people, taking a negative and fatalistic attitude, give it up as hopeless. No people (Tamils of Sri Lanka included) "deserve" occupation, subjection and subordination; humiliation and exploitation. To remain detached when injustice is perpetrated is to become part of that injustice.
-Sri Lanka Guardian
Lankapura said...
Err there is a Tamil parade in Wellawatta every year. One of my fondest childhood memories is of attending this every year. Is that a sign of subjugation of Colombo by Tamils.
Please learn to appreciate other cultures and value diversity.
To writer of this letter
You are showing your clear charctor about your self. If hindus pagent perahara in Galle or Colombo majority opposed?? answer is no so why you pin ball branic think this way
samuk
Celebarating any festival is correct. But at this sad time after killing more than 100 thousand tamils by chemical weapons and burried many alive, this is not correct, definitely mighty God will punish the killers.
SL said...
Many Tamils has the ideas similar to the author of this article. They want pluralism and the state sponsorships for religious and cultural events in the areas where they area minority but don't like even to have simple religious activity of their minorities in the regions where they area majority.


Are you that house that was labeled "that one that gives out oatmeal by the spoonful" and incur a hailstorm of flying eggs by 12PM? Well it's that time of year again, and while you may have not desired your house to be the belle of the Halloween ball, next year at the very least you can provide the neighbourhood children with a healthy treat that will leave your house yolk and TP free. Don't fret, help is here and ready to drop bombs of knowledge with more force than a skittles-binge hangover. The word will be spread, like organically sourced peanut butter on some whole grain toast, using my (probably not)patented three-step system.
Avoid the traditional culprits. While it may be mighty tempting to take the easy route and settle on that Costco brand 738-pack of off-brand Peanut M&Ms, it's important to consider that these options are cheap for just that reason; they're inexpensive and riddled with preservatives and artificial sweeteners. Spring for some naturally sweetened treats like these uniquely delicious lollipops in flavors like mango, watermelon, pomegranate, and blueberry.
Think outside the box (of chocolates). There's more out there than just Snickers and Starburst; get creative with your offerings. Don't be caught thinking that non-traditional options are limited to honeycrisp apples and granola bars; you can still offer some unique, healthy options without incurring the wrath of dozens of airborne eggs. There are plenty of alternatives that will leave you yolk-free such as these individually wrapped gummy bear packages.
They'll never notice the difference. As easy as it is to swiftly snag that sixty-six pack of supersized Snickers, there are much better options that will yield all the same fun without resulting in sugary stomach syndrome™. Made with cocoa from farmer co-operatives in developing countries, these bars of dark chocolately goodness are as ethical as they are delicious. They're also vegan, soy- and gluten-free; sorry "3 Musketeers", but those traits are the real triple threat.
So just remember, Halloween is about much more than leaving a sign that reads "please take just one" outside a locked door above a long-since empty bowlful of Sour Patch Kids. Don't be lazy, make sure that next Halloween, you bring a smile to kids' faces with the satisfaction of knowing those smiles will stay healthy for years to come.


The stock markets have gone into correction mode.
They have been breaching new peaks for the last couple of months but will for a while be in check mode.
The common query is that where should one invest money for higher returns or gains.
In 2014, this is a great option. The returns from investments in this segment were around 65% in 2013. The Short term dips do not take away from India being a potent investment zone for the next decade.
Invest money in IPOs though if the risk appetite is present because this is certainly not a fixed return option.
Real estate is still headed for further correction inspite of interest rate dips. For this sector to really provide higher returns, the June 2009 efficiencies must come back. Hence, invest your money in real estate.
Downtrends are also hinted by the over 50% ownership of investors along with possession dates seeing deferment with respect to recently launched projects. Preferable expected horizon should be long term.
One can go for equity linked savings schemes or ELSS mutual funds. Public provident funds or PPFs, and NSC or National Savings Certificates, are also eligible under section – 80 C.
One can also invest money in tax saving bonds such as notified NABARD or REC bonds which provide tax benefits as well as higher returns.
This option helps safeguard against market volatility due to wide portfolios held by them. For those looking to invest in chunks ultra short term or debt funds are better options as compared to les balanced equity inclined funds. Invest money in mutual funds through systematic investment plans (SIPs) for best returns.
The stock market has still not reached the January 2008 levels if inflation discounting is done for 5 years. The rupee is getting stronger with a new governor in Raghuram Rajan and a single majority party at the centre.
Currency appreciation and government trust high mean and less to no chances of a war, to invest your money in Gold and other precious metals will not be very wise.
The trading in the stock market is presently below historic averages considering inflation and other mitigating factors it is expected to go up. However, low beta value stocks will be preferable since a sustainable bull period environment is still absent.
Thus, investing money in stocks among other options is very desirable presently and for safer options one can always opt for debt bonds or the traditional fixed return options.


faceted understanding of the music they are learning.
Oshkosh Orchestra, and UW Oshkosh Early Music Ensemble.
Music Association and regularly judges Solo and Ensemble festivals.
about lessons or booking information.


C Channel Roll Forming Machine Technical Specifications of the C channel roll forming machine 1. Equipment feeding direction: left into the right out. 2. voltage parameters 380,50Hz, 3 phase. 3. Gas source: flow rate of 0.5m3 / min; pressure of 0.7MPa. 4.


text:
Pharmaceutical Investing News
Emerging Tech Investing>
Avricore Health Reports Third-Quarter 2022 Results
Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") today released its Q3 results which demonstrate significant revenue growth, indicating it can scale sustainably and deliver on its long-term objectives.
The Company's objective to create the world's first cloud-connected point-of-care network in community pharmacy is on track to becoming a reality, bringing powerful health screening and data management tools to community pharmacies and ensuring better outcomes for patients.
"Our target for this year has been to scale the HealthTab network, significantly increase revenues and make advancements toward profitability," said Hector Bremner, CEO of Avricore Health Inc. "In Q3 we've clearly demonstrated that we are achieving those goals."
The Company's discipline and focus have meant it has been able to fund its growth from existing capital. Through the effective implementation of its growth plan, the Company's HealthTab subsidiary, is operationally profitable, a significant milestone, and a clear indication that the Company is prepared to succeed in challenging times.
Visit www.sedar.com and search AVCR to review the consolidated financials for the Company.
HEALTHTAB™ – KEY DEVELOPMENTS
Key developments have included:
166 HealthTab™ systems were operating in Shoppers Drug Mart® and Loblaw family stores including pharmacist walk-in clinics as of September 30, 2022, 144 in Ontario and 15 in British Columbia, 4 in Nova Scotia and 1 in New Brunswick. Additionally, the Company was honoured to have Healthtab™ placed in the first pharmacist-led primary healthcare clinic located in Lethbridge, Alberta. Not only was this the first clinic, it was also the first system placed in a Real Canadian Superstore®, as well as its first Alberta location.
As of the date of this report 416 participating Shoppers Drug Mart® pharmacies and Loblaw family stores, have now received their HealthTab™ systems and are offering screening tests to patients. This innovative practice in healthcare delivery is expected to expand, as provinces struggle to recruit more family physicians. The program's primary focus is to screen patients at-risk for diabetes and cardiovascular disease. In-store signage and print material will let customers know they are able to request HealthTab™ tests, and existing patients will be made aware through direct outreach from their Shoppers Drug Mart® or Real Canadian Superstore® pharmacist based on their health profile.
As of July 1 st , 2022, the Government of Ontario brought into effect an expanded scope of practice for community pharmacists in the province, joining Alberta in this growing and popular approach. This includes limited prescribing for minor ailments, as well as the ability to perform certain point-of-care tests to assist patients with managing chronic disease. Approved tests include glucose, HbA1c and lipids, all of which HealthTab™ currently offers with the Abbott Afinion 2™. Also announced as part of this plan in Ontario, is a second stage of scope modifications, which will begin on January 1, 2023.
On September 29 th the BC Government announced significant changes to the scope of practice of community pharmacists with an implementation date expected in Spring 2023. While the current announcements covers some minor ailment prescribing power, extending prescription renewals and certain injections, the BC Ministry of Health is continuing to work with the BC College of Pharmacists on further moves which could align the province with others who have already allowed for more primary care services to be located in pharmacy, such as Alberta and Ontario.
During the pilot with Shoppers Drug Mart®, over 15,000 HealthTab™ tests were completed for more than 6,900 patients. The data collected confirmed that the patients tested had a high prevalence of previously undiagnosed diabetes, pre-diabetes and heart disease and significant near-term risk for major health events. Almost 60 percent of patients needed an intervention to better manage their chronic disease. On average, 31 percent received a new chronic medication, 28 percent required a change in their current medication, and 235 patients were newly identified as diabetic. Patients also reported in post surveys that they valued receiving this information from their pharmacists, and those pharmacists indicated that HealthTab™ enabled an increase in the value of services they were able to provide to their patients.
Developed a quality assurance program with a third-party reference laboratory to offer HealthTab pharmacies industry leading validation for point-of-care instruments and test consumables.
Developing new domestic pilot programs with national pharmacy chains.
Developing international programs and securing supplier agreements.
Evaluating wearable and evaluating continuous glucose monitoring integration.
QUARTERLY FINANCIAL INFORMATION
The following table highlights selected unaudited consolidated financial data for each of the eight most recent quarters that, in management's opinion, have been prepared on a basis consistent with the audited consolidated financial statements for the year ended December 31, 2021. These results are not necessarily indicative of results for any future period and you should not rely on these results to predict future performance.
Quarter Ended Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021 Dec 2020
$ $ $ $ $ $ $ $
Revenue 572,228 176,175 42,736 35,190 75,104 4,939 7,575 8,082
Gross profit (loss) 215,961 56,874 15,113 9,317 20,555 (998 ) 1,647 2,220
Share-based compensation 58,354 9,069 21,099 9,169 74,722 24,965 386,935 120,191
Comprehensive Loss 180,398 207,363 185,678 208,895 439,311 344,620 715,306 538,499
Net loss/Share (0.00 ) (0.00 ) (0.00 ) (0.00 ) (0.00 ) (0.00 ) (0.01 ) (0.00 )
Total Assets 2,128,017 1,985,085 2,122,816 2,281,393 2,517,569 2,541,099 2,740,053 440,090
RESULTS OF OPERATIONS FOR THE NINE MONTHS ENDING SEPTEMBER 30, 2022
The Company incurred a comprehensive loss of $573,439 for the nine months ending September 30, 2022 (2021 - $1,499,237). Significant changes are as follows:
Revenue increased to $791,139 (2021 - $87,618) due to an increase in HealthTab™ systems deployed and tests sold. Gross profit amounted to $287,948 (2021 – $21,204).
Expenses decreased to $867,186 (2021 – $1,482,097) a decrease of 41%, primarily due to a decrease in consulting, marketing and communications costs and share-based compensation expenses.
About Avricore Health Inc.
Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™, a wholly owned subsidiary, the company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.
About HealthTab™
HealthTab™ is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.
The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.
HealthTab™ Market Fast Facts
Point of Care Testing Market to reach $93.21 billion USD in 2030 ( Source )
Nearly 13.6 million Canadians expected to be diabetic or prediabetic by 2030, with many undiagnosed ( Source )
Over 1 in 3 Americans, approximately 88 million people, have pre-diabetes ( Source )
Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it's only after a heart attack they are diagnosed. ( Source )
There are more that 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in the UK.
Avricore Health Inc.
Hector Bremner, CEO 604-773-8943
info@avricorehealth.com
www.avricorehealth.com
Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.
Avricore HealthTSXV:AVCREmerging Tech Investing
AVCR:CA
Avricore Health
The point-of-care testing (POCT) market is expected to reach US$103.2 billion by 2030 from US$40.6 billion in the year 2021 at a CAGR of 10.92 percent from 2022 to 2030.
The accessibility of POCT has been an increasing priority of the world's leading health organizations and experts. Pharmacies are ideal 'hubs' within the community to offer patients better access to the numbers they need to know for preventing or treating conditions such as diabetes and heart disease or the timely diagnosis of infection.
Avricore Health Inc. (TSXV:AVCR, OTCQB: AVCRF) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™ (a wholly owned subsidiary), its mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.
HealthTab™ is a turnkey point-of-care testing solution that effectively turns pharmacies into diagnostic hubs (sometimes known as 'Community Diagnostic Centres' or CDCs) and connects them on a single, cloud-based platform.
The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including: equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real-world data (RWD) sets, and third-party app integration through API. In June 2021, Avricore signed a master agreement with select Shoppers Drug Mart pharmacies to pilot the HealthTab™ platform. This agreement allows patients access to point-of-care blood screening and health-data management for potential risks for developing diabetes and cardiovascular conditions through the HealthTab™-integrated Afinion 2™ analyzers by Abbott Rapid Diagnostics.
Avricore is the first pharmacy solutions provider to partner with Abbott (NYSE:ABT), the global healthcare company and diagnostics leader in Canada. In May 2021, it signed a supplier distribution agreement to expand the distribution of Abbott's Afinion 2™ and associated tests for diabetes and heart disease screening in community pharmacies in Canada. This agreement includes valuable HbA1c testing, a critical marker for the screening and management of diabetes.
Near-term goals for the company include expansion into more pharmacies across Canada, followed soon after by entering the US and UK markets. It has made significant strides in testing and developing its technology and is moving into the commercialization stage.
Strategic partnerships like Abbott and pharmacy-focused pilot opportunities advance Avricore closer to becoming an incredibly dominant player in the community diagnostics space. The company aims to make actionable health information more accessible for everyone by creating the world's largest rapid testing network in pharmacy.
Avricore Health Inc is a pharmacy solutions provider that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues
The wholly owned subsidiary, HealthTab™, offers fast, accurate and cost-effective point-of-care screening. With just a few drops of blood from a finger prick, results are available on the spot and data is available in real time.
The current test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g. HbA1c, Lipid Profile, eGFR). HealthTab™ also recently added capabilities for bacterial and viral tests, such as strep and COVID-19
The company leverages strategic partnerships with notable names in the diagnostic space, including Abbott Rapid Diagnostics, a global healthcare company and leader in diagnostics. This partnership allows Avricore to use Abbott's Afinion 2™ analyzer to offer high-quality, low-cost screening tests
In June 2021, Avricore announced its master agreement to pilot its HealthTab™ platform for diabetes management in select Shoppers Drug Mart pharmacies
Avricore's ultimate aim is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacy
The company expanded patient testing with the HealthTab™ platform in select Shoppers Drug Mart® pharmacies in British Columbia, bringing its diabetes screening program to Western Canada for the first time.
Avricore's leadership team brings a diverse portfolio of expertise across healthcare and biotech industries as well as technology, finance and communications. Together, they share a common vision for moving pharmacy forward and have positioned the company for significant future growth and expansion.
Hector Bremner - CEO
Hector Bremner has over fifteen years of senior and executive experience across various industries, including international trade, natural gas, marketing and communications. He has owned and operated TOUCH Marketing, a boutique marketing and communication firm based in Vancouver, from 2007 to 2013.
Bremner has also served as the executive assistant to the Deputy Premier and Minister of Natural Gas Development, Responsible for Housing, as well as the Minister of International Trade and Minister of Small Business. In 2015, he joined Vancouver's Pace Group Communications as vice-president of public affairs.
David Hall - Chairman
David Hall's leadership spans five different companies. Aside from acting as chairman and director at Avricore, he is also currently the chairman of RepliCel Life Sciences, and a member of the board of TrichoScience Innovations, AdvantageBC and Providence Health Care Research Institute.
Hall also served as chairman of Perceptronix Medical, Inc., chief financial officer, secretary and treasurer of Angiotech Pharmaceuticals, Inc., president and director at Newcastle Resources Ltd. and chairman for LifeSciences British Columbia.
Kiki Smith - CFO
Kiki Smith has over 20 years of experience assisting private and public companies in the roles of accountant, corporate controller and CFO in mining, oil & gas, real estate, high technology, food production and investment fund management. She currently provides consulting services in M&A, financial reporting and regulatory compliance to several public and private companies across several investment sectors.
Smith is also a member of the Chartered Professional Accountants of British Columbia. She has a bachelor's degree in economics from the University of British Columbia.
Rodger Seccombe - CTO
Rodger Seccombe is the co-founder and former CEO of HealthTab™ Inc. He has over 20 years of experience launching and running companies in software, healthcare technology and clean energy. Seccombe is a recognized industry expert in direct-to-consumer and point-of-care testing technology.
In 2006, he joined the start-up team at Canadian Bioenergy Corporation and helped pioneer the development of the renewable fuel industry in Canada. Before HealthTab™, he designed and developed cloud-based informatics systems currently in use by some of the world's leading medical laboratories and instrument manufacturers.
Avricore to Present at Emerging Growth Conference on Oct. 26, 2022
Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is excited to present at the Emerging Growth Conference on October 26 th .
This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO, Hector Bremner in real time on the Company's current activities. After a short presentation, the floor will be subsequently opened for questions, where Mr. Bremner will do his best to get through as many of them as possible.
Call Details:
October 26, 2022 @ 11:30am PT / 2:30pm ET
Please register here to ensure you can attend the conference and receive any updates that are released: https://goto.webcasts.com/starthere.jsp?ei=1575084&tp_key=b452034330&sti=avcrf
*If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on www.EmergingGrowth.com and we will also release a link to that after the event .
The 30-minute call agenda will be as follows:
15Min: Overview Presentation
15Min: Q&A
We're looking forward to seeing you there, please review our most recent investor presentation here: www.avricore.com
About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.
The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.
All sessions will be conducted through video webcasts and will take place in the Eastern time zone.
Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it's only after a heart attack they are diagnosed ( Source )
There are more than 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in the UK.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy.
HealthTab Roll Out on Track and Operations Cashflow Positive
Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is pleased to provide this corporate update on the Company's execution expanding its powerful chronic-disease screening and reporting platform, HealthTab.
On August 8 th , the Company announced a new Master Service Agreement and Statement of Work was signed with Shoppers Drug Mart pharmacies to significantly expand the HealthTab point-of-care testing platform to up to 450 locations nation-wide, with affiliated locations under the Loblaw family of brands being included.
"The team has been exceptional in deploying systems and we have already deployed more than half of the target locations," said Hector Bremner, Avricore Health's CEO. "We are on track to achieve the late-November target for full deployment."
Once a pharmacy has HealthTab onsite there is a period of training and acclimating teams with the workflow. Nevertheless, data from locations is indicating strong utilization and patient uptake, generating strong consumables-based revenues.
In fact, HealthTab already has positive cash-flow from operations and is expected to significantly ramp up gross revenues over the next 12 months yielding target margins and profitability by Q2 2023.
Supporting the optimism of strong and sustainable growth are the anticipated policy and funding announcements related to point-of-care in community pharmacy by the federal and provincial governments in the coming weeks and months. These changes and commitments will have a significant impact on sales volumes in 2023, not to mention demand from pharmacy groups to install HealthTab.
For example, on October 5 th , the Government of Canada tabled its Framework for Diabetes in Canada, which lays out an aggressive strategy to better screen, surveil, prevent, and manage this disease which currently costs $30 Billion CAD annually to treat. To find the details, please visit:
https://www.canada.ca/en/public-health/services/publications/diseases-conditions/framework-diabetes-canada.html
Also, in addition to Alberta and Ontario, British Columbia recently announced their plan to expand the scope of pharmacy practice, which includes limited prescribing as of October 14 th , and makes further commitments to work with the profession to identify additional ways they can contribute to healthcare solutions, such as chronic disease screening and support, as in other jurisdictions. To learn more, please visit: https://news.gov.bc.ca/releases/2022HLTH0059-001464
Internationally, policy and funding supporting more scope for pharmacists to tackle chronic disease and alleviate the pressures being faced for primary care also give a great deal of confidence that HealthTab's objective of being the world's leading point-of-care solution for pharmacy has a bright future. The coming weeks and months are expected to bring positive news and new opportunities for our current EU, UK and US program initiatives.
Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release.
Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy
Avricore Health Announces CEO Update Call on Sept. 22, 2022
Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is excited to offer a live discussion on the Company's current activities and forward outlook as it executes a significant national scale-up of its pharmacy-based point-of-care platform, HealthTab.
"We're currently deploying a significant expansion of HealthTab systems and we're on track to achieve our revenue goals, as well as getting to cash flow positivity," said Avricore Health CEO, Hector Bremner. "It's an exciting time for the Company and we're looking forward to discussing the recent successes and future objectives."
September 22, 2022 @ 11:00am PT / 2:00pm ET via Zoom
Register here to receive login details: Investor@avricorehealth.com
10min: Opening Remarks / Team Introductions
30Min: Overview Presentation and Update
Avricore Health Supports the Globe and Mail's Health Innovation Event
Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") was honoured to join the Globe and Mail's recent Health Care Innovation event, featuring leaders from various corners of the sector, including Company CEO, Hector Bremner.
"With about 40% of patients in Canada saying it's difficult to access a diagnostics test and nine million expressing difficulty in getting access to care, it's clear that the time is now to support more services in community pharmacy," says Avricore Health Inc. CEO, Hector Bremner. "HealthTab is already playing a significant role in supporting better services in pharmacy and we're going to continue to advocate for patients, and providers, so better outcomes for all are achieved."
The Globe and Mail's event featured health sector leaders, academics, governmental agency representatives, physicians, and patient advocates. For a full list of participants and to watch the webcast in its entirety, it can be viewed at the Globe and Mail's site at the following link: https://www.theglobeandmail.com/events/article-new-approaches-to-health-care-delivery/ .
Also, for reference to the above-mentioned observations on Canadian patient experience and sentiment around the current healthcare challenges, please view the recent Angus Reid Institutes series of polling data here: https://angusreid.org/canada-health-care-issues/ .
Point of Care Testing Market to reach $93.21 Billion USD in 2030 ( Source ).
Nearly 13.6 Million Canadians expected to be diabetic or prediabetic by 2030, with many undiagnosed ( Source ).
Over 1 in 3 Americans, approximately 88 million people, have pre-diabetes ( Source ).
Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it's only after a heart attack they are diagnosed ( Source ).
Alkaline Fuel Cell Power Corp. Announces AGM Results
Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) ("AFCP" or the "Company") a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, is pleased to announce the results of voting at its annual general meeting (" AGM ") of shareholders which was held on January 25, 2023 in person in Vancouver, British Columbia and by conference call (the " Meeting "). There were 19 shareholders represented in person or by proxy at the Meeting holding 2,423,369 common shares, representing 1.39% of the Company's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting is set out below:
Number of Directors
The board of directors received a written resignation from Joel Dumaresq on January 12, 2023. Therefor Management proposed to determine the number of seats on the board of directors be set at four (4) instead of five (5) as presented in the Company's information circulated dated December 21, 2022 and the resolution be amended accordingly.
The resolution to set the number of directors of the Company at four (4) was approved by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting.
Voting results are set out below:
Votes For Votes Against
# % # %
2,422,814 99.977% 555 0.023%
Election of Directors
Each of the nominees for election as director listed in the Company's management information circular dated December 21, 2022 were elected as directors of the Company for the ensuing year until their successors are elected or appointed. Voting results are set out below:
Votes For Votes Withheld
Troy Grant 2,344,214 96.734 % 79,155 3.266 %
Maciej Lis 2,422,214 99.952 % 1,155 0.048 %
Matthew Fish 2,419,214 99.829 % 4,155 0.171 %
Richard Lu 2,420,214 99.870 % 3,155 0.130 %
Appointment of Auditors
Dale Matheson Carr-Hilton Labonte LLP, Chartered Professional Accountants were reappointed as Auditors of the Company for the ensuing year with their remuneration to be fixed by the Board of Directors. Voting results are set out below:
2,419,089 99.823% 4,280 0.177%
Approval of Other Matters
The resolution to transact such other business that may be brought properly before the Meeting and any adjournment or postponement of the Meeting. Voting results are set out below:
2,344,689 96.753% 78,680 3.247%
Following the AGM and the resignation of Joel Dumaresq from the Company's Board of Directors, the Audit Committee will be comprised of Troy Grant (Chair) Maciej Lis and Richard Lu. In addition, the Compensation Committee will be comprised of Matthew Fish (Chair), Maciej Lis and Troy Grant.
ABOUT ALKALINE FUEL CELL POWER CORP. (NEO: PWWR)
AFCP is a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech. We bring 'Power to the People' today, combining a stable revenue stream with a future- forward vision to commercialize our advanced hydrogen fuel cell technology to meet the massive global market need, and ultimately generate compelling returns for investors.
AFCP operates through two global entities: Fuel Cell Power NV, a wholly owned subsidiary in Belgium, and PWWR Flow Streams ("PWWR Flow"), an AFCP brand in Canada.
Fuel Cell Power NV is focused on the development, production and commercialization of micro- combined heat and power ("micro-CHP") systems and off-grid and back-up power generators based on advanced alkaline fuel cell technology that generates zero CO2 emissions. Fuel Cell Power NV is working through milestones to deliver a commercialized alkaline fuel cell in 2024.
PWWR Flow is focused on the development, ownership and operations of combined heat and power ("CHP") assets. PWWR Flow assets deliver efficiency improvements of over 20% with reduced costs to customers in multi-residential and commercial applications. PWWR Flow has contracted existing CHP assets in Toronto, Canada, and has an additional pipeline of potential contracts valued at over $50 million currently in development.
AFCP is well positioned to deliver 'Power to the People' in the global energy transition while offering a diversified cleantech growth platform for investors.
Further information is available on the Company website at https://www.fuelcellpower.com/ , and the Company encourages investors and other interested stakeholders to follow it on:
LinkedIn, Twitter, Facebook, Instagram and YouTube. Common shares are listed for trading on the NEO under the symbol " PWWR ", the OTC Venture Exchange " OTCQB " under the symbol " ALKFF " and on the Frankfurt Exchange under symbol " 77R " and " WKN A3CTYF ".
Frank Carnevale
+1 (647) 531- 8264
fcarnevale@fuelcellpower.com
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. In certain cases, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "forecasts", "intends", "anticipates", "believes" or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "achieve". Forward-looking statements in this news release may include, but are not limited to, the issuance of RSUs, the vesting of the RSUs, statements with respect to the Company's technology, intellectual property, business plan, objectives and strategy.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward- looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
NEITHER THE NEO EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE NEO EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Alkaline Fuel Cell Power Announces Resignation of Director
Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) ("AFCP" or the "Company") a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, announces the resignation of Joel Dumaresq as director, effective January 12, 2023. Mr. Dumaresq will remain as the Chief Financial Officer of the Company while the Company seeks a suitable replacement.
ABOUT Alkaline Fuel Cell Power CORP.
The Company is a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech. We bring 'Power to the People' today, combining a stable revenue stream with a future- forward vision to commercialize our advanced hydrogen fuel cell technology to meet the massive global market need, and ultimately generate compelling returns for investors.
The Company operates through two global entities: Fuel Cell Power NV, a wholly owned subsidiary in Belgium, and PWWR Flow Streams ("PWWR Flow"), a Company brand in Canada.
The Company is well positioned to deliver 'Power to the People' in the global energy transition while offering a diversified cleantech growth platform for investors.
This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. In certain cases, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "forecasts", "intends", "anticipates", "believes" or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "achieve". Forward-looking statements may include, but are not limited to, statements with respect to the Company's technology, intellectual property, business plan, objectives and strategy.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Accordingly, readers should not place undue reliance on the forward‐looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
BriaCell CEO Letter to Shareholders
Positive FDA feedback on our pivotal study for lead clinical candidate Bria-IMT™ in combination with a checkpoint inhibitor could greatly accelerate the path to commercialization.
Successful completion of the pivotal study could be followed by a Biologics License Application submission and commercialization.
Pivotal study's primary endpoint to be linked to survival improvement.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, today issues a letter to shareholders from Dr. William V. Williams, BriaCell's President and CEO.
Dear BriaCell Shareholders,
I am writing this letter to share our tremendous excitement with our recent Bria-IMT™ FDA milestone, and to provide insights into our upcoming Bria-OTS™ personalized treatment program. We strongly believe our novel immunotherapy candidates will transform the way we treat cancer patients.
Our Lead Program and Value Driver: Bria-IMT™
Last week , we received positive feedback from the FDA and are progressing towards our pivotal study initiation for Bria-IMT™ in combination with an immune checkpoint inhibitor in advanced metastatic breast cancer (under Fast Track designation). Rather than working through multi-year Phase II and Phase III trials, successful completion of the pivotal study would allow us to subsequently submit a Biologics License Application and greatly accelerate the path to commercialization.
The FDA agreed on the eligible patient population for the study: breast cancer patients who have failed the available approved therapies. These are women in desperate need of therapy to extend their lives. The FDA also agreed on our preferred primary endpoint of survival improvement in comparison to the patient physician's choice of treatment. Note that the average survival in this very sick patient population is under one year and as little as weeks in women who have progressed through multiple regimes. These women need help!
We are speeding up clinical preparations in parallel as we finalize the pivotal study protocol with the FDA in the coming months. We have boosted our Bria-IMT™ production batches and testing capabilities required for larger scale patient dosing. Frequent and responsive FDA communication under our Fast Track status has greatly accelerated protocol review and feedback timelines. We could initiate patient dosing as early as the second quarter of 2023.
Our recently reported cash position is US$37 million. Subject to finalizing the pivotal study protocol and associated costs, we are in the enviable position of being able to drive this program forward without the need to raise additional financing.
Learning from our Top Responders: Our Bria-OTS™ Program
With BriaCell's newly issued patent , protecting the composition of matter and method of use of BriaCell's personalized off-the-shelf whole-cell immunotherapies, BriaCell expects to begin dosing advanced metastatic breast cancer patients in its Bria-OTS™ Phase I/IIa clinical study in the first half of 2023.
We believe this unique approach will maximize patient responses by "HLA matching" each patient, identifying her human leukocyte antigen (HLA) type prior to dosing through a simple saliva test. We then treat her with pre-manufactured cells that correspond to her HLA type. We call this matching approach Bria-OTS™ or Off-The-Shelf. This novel treatment approach came about when we found that the HLA type of our previously disclosed top responders matched with the Bria-IMT™ cell-line HLA type.
The treatment will be "personalized" because the cell therapy will match the HLA type of the patient, even though it is pre-manufactured.
As a physician who has been involved in drug development for over 25 years, I can state without hesitation that I am absolutely thrilled with our recent progress and very proud of the world-class team we have assembled at BriaCell. We continue to strive towards solutions for cancer patients whose medical needs are unmet and look forward to sharing more exciting news with you in the coming months.
I want to end this letter by thanking all our shareholders who have continued to support us throughout our journey, as well as our employees, board members, scientific advisory board, collaborators, and clinical teams who have worked tirelessly to make these clinical advancements possible. Finally, I would like to offer our sincerest thanks to our patients and their families for their patience and trust in our science and technology. I am looking forward to a great year in 2023.
William V. Williams, MD
BriaCell Therapeutics Corp.
About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/ .
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Examples of forward-looking statements in this news release include statements that the Company makes regarding the ability of the pivotal study to greatly accelerate the path to commercialization; the potential for the Company to make a Biologics License application for the approval of the combination regimen; the potential initiation of patient dosing in the first half of 2023; the ability to drive the pivotal study program forward without the need to raise additional funding; and the Company's ability to address alleged illegal activities intended to depress the Company's share price. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov . Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
info@briacell.com
Jules Abraham
Director of Public Relations
CORE IR
julesa@coreir.com
investors@briacell.com
BriaCell to Investigate Alleged Illegal Trading of Public Securities
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announced today that it has approved measures to address alleged illegal trading activity of its publicly traded securities. The Company believes that certain individuals andor companies may have engaged in manipulative andor suspected illegal trading practices that may have artificially depressed its share price. As a result, BriaCell is implementing a plan to address this issue which may include legal action.
BriaCell is working to build one of the leading immuno-oncology companies in the biotech sector with a singular focus on commercializing our novel immunotherapy approach for cancer patients. While our clinical team remains dedicated to developing these desperately needed therapies, the Company recognizes that recent milestones have been achieved with the support of loyal investors who are instrumental in the ongoing development of our assets. By taking action to protect the interests of our shareholders, we are also protecting the interests of the Company and the tens of thousands of cancer patients in need of effective treatment options. To this end, BriaCell is pursuing avenues to address alleged illegal activities carried out by various parties potentially working collusively with the intent of depressing the Company's share price while undermining the interest of our shareholders.
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Examples of forward-looking statements in this news release include statements that the Company makes regarding the Company's plans to address alleged illegal activities carried out by various parties potentially working collusively with the intent of depressing the Company's share price which may include legal action. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov . Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Alkaline Fuel Cell Power Corp. Announces Grant of Restricted Share Units
Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) (" AFCP " or the " Company "), a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, is pleased to announce that the Company has granted an aggregate of 9,541,557 restricted share units (" RSUs ") to certain arm's-length consultants of the Company (each, a " Consultant ").
The RSUs will vest in accordance with the terms of each Consultant's RSU agreement and in accordance with the Company's 2021 RSU Plan. Upon vesting, each RSU entitles the holder thereof to receive one common share in the capital of the Company.
REPEAT - Alkaline Fuel Cell Power Corp. Announces Prototype Launch of Jupiter 1.0, a Powerful Fuel Cell System for Homes and Small Buildings, and Management Update
Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) (" PWWR " or the " Company "), a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, is pleased to announce that its wholly owned Belgium subsidiary, Fuel Cell Power NV (" FCP NV "), has launched the prototype of its micro-combined heat and power (" CHP ") fuel cell, named Jupiter 1.0 .
"Alkaline Fuel Cell Power is proud to present the prototype of our fuel cell system for homes and small buildings - Jupiter 1.0," stated Frank Carnevale, Chief Executive Officer of PWWR. "The Jupiter 1.0 prototype will be piloted with select strategic partners to demonstrate the advantages of delivering green hydrogen to homes and small buildings, globally. We thank staff for their dedication and effort to complete this important milestone on time."
Figure 1- FCP NV development team with completed fuel cell system prototype - Jupiter 1.0
Jupiter 1.0
The planet Jupiter is made up of roughly 90% hydrogen, and similarly, this PWWR fuel cell converts hydrogen to heat and electricity at approximately 90% efficiency. Jupiter 1.0 is built to supply power during peak demand periods and serves as a back-up when required for homes and small buildings.
Jupiter 1.0 has successfully demonstrated its capabilities by powering several appliances and providing hot water within the Company's Belgian facility. At capacity, Jupiter 1.0 is expected to deliver approximately 7kW for the first hour of use, with a 4kW electrical output afterward representing approximately 3.2 kWh equivalent in heating output. The use of internal batteries enables Jupiter 1.0 to deliver higher peak power when called upon in the first hour of use. Over the coming months, additional enhancements will be made to the system prior to submission for CE-certification (a regulatory standard that verifies certain products are safe for sale and use in the European Economic Area) and prior to pilot projects.
PWWR has been working to optimize innovation for hydrogen-powered fuel cells that operate in an alkaline environment, which offer meaningful cost benefits. Such technology, and therefore Jupiter 1.0, requires fewer components compared to conventional fuel cells and also eliminates the need for expensive, precious metals such as platinum which have traditionally been required in the electrodes. PWWR's systems will therefore be more cost-effective to build and offer a competitive advantage over existing fuel cells. Jupiter 1.0 is currently stationed in the FCP NV plant in Belgium.
Figure 2- Jupiter 1.0 delivering power and heat to appliances and a boiler
As announced on September 20, 2022 and November 22, 2022 , PWWR is in the process of negotiating two pilot projects which will demonstrate the mutual technologies and business cases with the use of hydrogen extraction from natural gas pipelines, and the use of ammonia converted to hydrogen as a back-up power solution for remote sites. PWWR, in coordination with its partners, continues to narrow down sites for these pilots, and will provide ongoing updates as developments are confirmed.
Management Update
With the launch of Jupiter 1.0, PWWR moves into a more strategic focus on the completion of prototypes for CE-certification and deployment in pilot projects. Jo Verstappen, Managing Director of FCP NV has resigned in his role. The Company offers its gratitude and appreciation for his guidance to launch the prototype. Frank Carnevale, Chief Executive Officer of Alkaline Fuel Cell Power Corp, has assumed management of FCP NV, and is actively reviewing and developing the commercialization strategies and tactics to bring Jupiter 1.0 and fuel cell generator to markets, globally.
The Company is a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech. We bring 'Power to the People' today, combining a stable revenue stream with a future-forward vision to commercialize our advanced hydrogen fuel cell technology to meet the massive global market need, and ultimately generate compelling returns for investors.
Fuel Cell Power NV is focused on the development, production and commercialization of micro-combined heat and power ("micro-CHP") systems and off-grid and back-up power generators based on advanced alkaline fuel cell technology that generates zero CO2 emissions. Fuel Cell Power NV is working through milestones to deliver a commercialized alkaline fuel cell in 2024.
Alkaline Fuel Cell Power Corp
www.fuelcellpower.com
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. In certain cases, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "forecasts", "intends", "anticipates", "believes" or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "achieve". Forward-looking statements in this news release may include, but are not limited to, expectations and intended use of CHP system, Juniper 1.0; efficiencies of the CHP system; the ability to successfully bring the CHP system to market; future pilot projects of the Company and future strategic initiatives and plans of the Company and FCP NV.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/418691fc-3249-4b23-89fd-4d33359eae01
https://www.globenewswire.com/NewsRoom/AttachmentNg/dd7508c7-5de0-4efd-b162-95ac0fb6b44a


Missouri River Regional Library meeting rooms will be available free of charge during normal library operating hours to nonprofit community groups and organizations sponsoring meetings and programs open to the public. Library programs and activities have first priority for use of meeting rooms.
A meeting room application must be filled out completely and on file prior to first use of room. Reservations may be made by telephone; however an application still needs to be completed and on file with the Library. The individual initiating the request will be considered the official representative of the group and will assume responsibility for communicating meeting room regulations to the group. Such individual must be at least 18 years of age.
A $25 deposit is required for all meeting room use. It will be returned if the meeting room is left in good condition. Groups scheduling for multiple dates will be allowed to maintain a deposit on file.
To provide an opportunity for all groups to use MRRL's meeting spaces; groups are permitted to use rooms no more than once per month for regularly scheduled meetings.
Meeting rooms may be scheduled for the current year. Scheduling for the following year will open on December 1st.
Meetings and programs must be free and open to the public, except meetings legitimately closed per state statue. No charges, fees, collections or solicitations are allowed on Library property.
The Library reserves the right to approve or disapprove any application at the Library Director's discretion and limit the use of the rooms.
Groups are responsible for their own room arrangement. Tables and chairs can be found in the rear storage area of the Art Gallery/Multipurpose Room. The Library has a limited number of tables in the meeting rooms. Please consider this when setting up.
Groups are responsible for clean-up and must return all furniture to the rear storage area when their meeting ends. If a violation occurs the group will no longer be permitted to use the room and the group's deposit will be forfeited.
Meetings must be over in sufficient time to clean-up and vacate the building by closing time. No meetings, set-up, or clean-up may begin before or extend after regular library hours.
The Library will provide no audio/visual equipment to outside groups. The only exception is groups may use the projector screen located in the Art Gallery/Multipurpose Room.
Groups may use their own audio/visual equipment in the meeting rooms and are responsible for their own technical support, extension cords, etc.
The official representative of the group will be responsible for the orderly conduct of the group and for any damages to library property or equipment. Everyone using the meeting rooms shall adhere to the Library's Patron Code of Conduct policy and procedures.
The Library's multipurpose room serves at the MRRL Art Gallery. Under no circumstances shall anyone attending a meeting in said room touch or attempt to move any of the art on display. Any loss or damage to an exhibit which occurs during a meeting shall be the financial responsibility of the organization and/or the individual reserving the room.
A telephone for use by the public is not available in the meeting rooms. Library staff will not accept telephone messages for persons attending meeting room functions. A pay phone is located on the main floor.
Tobacco use is not permitted in the Library or on its grounds.
Food and non-alcoholic beverages may be served. All food and drink must be kept in the meeting room. Groups must provide all supplies and service pieces. The group must request kitchen facilities when scheduling the room. The kitchen must be cleaned and left in the same condition as found.
The Library assumes no responsibility for any materials or items left on the premises.
Use of the Library's meeting rooms does not constitute endorsement by the Library of points of view expressed by the group. No advertisement or announcement implying such endorsement or sponsorship will be permitted, including use of Library's name or Logo.
In the event of an emergency, the Library Director reserves the right to cancel meeting room reservations. In the event of severe weather conditions, a group representative will be responsible for listening to local radio stations or checking the library's website for closing announcements. Groups will not be notified of Library closings due to weather.
If a meeting is cancelled, please notify the Library as soon as possible.
Missouri River Regional Library is committed to compliance with the Americans with Disabilities Act. Reasonable modifications will be provided upon prior request.